Top

Current Hepatology Reports

Published in:

06-02-2024 | Review

Expanding the Donor Pool for Liver Transplantation: Assessing the Potential Use of HBV-Positive Allografts

Authors: Philip Vutien, Mindie H. Nguyen

Published in: Current Hepatology Reports | Issue 2/2024

Abstract

Purpose of Review

This review summarizes the feasibility, benefits, and concerns of utilizing hepatitis B virus (HBV)-positive allografts for liver transplant.

Recent Findings

Analyses of registry-based and multi-center cohorts, in this current era of high-barrier nucleos(t)ide analogue therapies, have shown that recipients of HBV-positive allografts have long-term graft and recipient rates comparable to recipients of HBV-negative allografts. The utilization of HBV-positive allografts can also be cost-effective. However, early evidence indicates that for recipients with hepatocellular carcinoma (HCC), the utilization of HBV-positive allografts may increase the risk of recurrent HCC and mortality.

Summary

Although HBV-positive allografts have the potential to expand the organ pool and shorten candidate waitlist times and mortality, certain recipient subgroups including those with HCC require closer attention and additional data. There are also important economic and ethical issues surrounding informed consent, equity, society stigma, and transparency to consider.

https://www.optn.transplant.hrsa.gov/data/view-data-reports/national-data/. Accessed 30 Sep 2023.

Rana A, Gruessner A, Agopian VG, Khalpey Z, Riaz IB, Kaplan B, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150(3):252–9. https://doi.org/10.1001/jamasurg.2014.2038.CrossRefPubMed

Mazumder NR, Atiemo K, Kappus M, Cullaro G, Harinstein ME, Ladner D, et al. A comprehensive review of outcome predictors in low MELD patients. Transplantation. 2020;104(2):242–50. https://doi.org/10.1097/TP.0000000000002956.CrossRefPubMedPubMedCentral

Nekrasov V, Matsuoka L, Rauf M, Kaur N, Cao S, Groshen S, et al. National outcomes of liver transplantation for model for end-stage liver disease score >/=40: the impact of Share 35. Am J Transplant. 2016;16(10):2912–24. https://doi.org/10.1111/ajt.13823.CrossRefPubMed

Thuluvath PJ, Bruno DA, Alukal J, Satapathy SK, Thuluvath AJ, Zhang T. Use of HCV-positive livers in HCV-negative recipients. Am J Gastroenterol. 2020;115(7):1045–54. https://doi.org/10.14309/ajg.0000000000000583.CrossRefPubMed

Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(8):524–37. https://doi.org/10.1038/s41575-023-00760-9.CrossRefPubMed

World Health Organization: Hepatitis B Fact Sheet. 2023. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed September 2, 2023.

Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis. Clin Transplant. 2011;25(3):E243–9. https://doi.org/10.1111/j.1399-0012.2011.01409.x.CrossRefPubMed

Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation. 2003;75(8):1179–86. https://doi.org/10.1097/01.TP.0000065283.98275.FE.CrossRefPubMed

10.

Duvoux C, Belli LS, Fung J, Angelico M, Buti M, Coilly A, et al. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. Aliment Pharmacol Ther. 2021;54(5):583–605. https://doi.org/10.1111/apt.16374.CrossRefPubMed

11.

Te H, Doucette K. Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant. 2019;33(9):e13514. https://doi.org/10.1111/ctr.13514.CrossRefPubMed

12.

McPherson S, Elsharkawy AM, Ankcorn M, Ijaz S, Powell J, Rowe I, et al. Summary of the British Transplantation Society UK guidelines for hepatitis E and solid organ transplantation. Transplantation. 2018;102(1):15–20. https://doi.org/10.1097/TP.0000000000001908.CrossRefPubMed

13.

• Ali SE, Vutien P, Bonham CA, Landis C, Kwo P, Esquivel C, et al. Use and outcomes of hepatitis B virus-positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021. Liver Transpl. 2023;29(1):80–90. https://doi.org/10.1002/lt.26543. (In this registry-based study of the Organ Procurement and Transplantation Network dataset, there was no significant difference between survival rates for recipients of HBV-positive allografts (n = 204) as compared to matched recipients (n = 204) of HBV-negative allografts (3-year survival 84.8% for HBV-positive vs. 82.3% for HBV-negative, logrank p = 0.95).)CrossRefPubMed

14.

• Yu S, Cen C, Zhang X, Cheng L, Xia W, Jia J, et al. Utilization of hepatitis B virus surface antigen positive grafts in liver transplantation: a matched study based on a national registry cohort. J Gastroenterol Hepatol. 2022;37(6):1052–9. https://doi.org/10.1111/jgh.15821. (In this analysis of the China Liver Transplant Registry, the authors report no significant difference between survival rates for recipients of HBV-positive allografts (n = 503) as compared to matched recipients (n = 503) of HBV-negative allografts (5-year survival 66.7% for HBV-positive vs. 65.7% for HBV-negative, p = 0.22).)CrossRefPubMed

15.

• Yu J, Shi X, Yu H, Wu J, Ma J, Dong S, et al. Impact of hepatitis B surface antigen positive grafts on liver transplantation in patients with benign and malignant liver disease. J Med Virol. 2022;94(7):3338–48. https://doi.org/10.1002/jmv.27703. (In this retrospective observational study of patients transplanted at two centers in China, the authors found that the receipt of HBsAg-positive liver, as compared to receipt of a HBsAg-negative liver, was independently associated with a significantly elevated risk of recurrent HCC (adjusted HR 1.73, 95% CI 1.20–2.48).)CrossRefPubMed

16.

Delman AM, Turner KM, Safdar K, Anwar N, Silski LS, Lee TC, et al. Expanding the donor pool: first use of hepatitis B Virus Nat positive solid organ allografts into seronegative recipients. Ann Surg. 2021;274(4):556–64. https://doi.org/10.1097/SLA.0000000000005071.CrossRefPubMed

17.

Lu D, Yang F, Zhuo J, Yang M, Lin Z, Jin P, et al. The matching status between donor and recipient hepatitis B seroepidemiology makes a difference in liver transplantation for hepatocellular carcinoma. Clin Transl Gastroenterol. 2020;11(5):e00168. https://doi.org/10.14309/ctg.0000000000000168.CrossRefPubMedPubMedCentral

18.

Lee TC, Kaiser TE, Luckett K, Wima K, Winer LK, Morris MC, et al. Use, safety, and effectiveness of viremic hepatitis B virus donor livers: a potential opportunity to expand the donor pool. Liver Transpl. 2019;25(10):1581–4. https://doi.org/10.1002/lt.25595.CrossRefPubMed

19.

Wei L, Chen D, Zhang B, Zhao Y, Liu B, Shi H, et al. Long-term outcome and recurrence of hepatitis B virus following liver transplantation from hepatitis B surface antigen-positive donors in a Chinese population. J Viral Hepat. 2018;25(12):1576–81. https://doi.org/10.1111/jvh.12972.CrossRefPubMed

20.

Ballarin R, Cucchetti A, Russo FP, Magistri P, Cescon M, Cillo U, et al. Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. World J Gastroenterol. 2017;23(12):2095–105. https://doi.org/10.3748/wjg.v23.i12.2095.CrossRefPubMedPubMedCentral

21.

Jeng LB, Thorat A, Yang HR, Yeh CC, Chen TH, Hsu CH, et al. Successful use of hepatitis B surface antigen-positive liver grafts - an effective source for donor organs in endemic areas: a single-center experience. Ann Transplant. 2015;20:103–11. https://doi.org/10.12659/AOT.893032.CrossRefPubMed

22.

Yu S, Yu J, Zhang W, Cheng L, Ye Y, Geng L, et al. Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation. J Hepatol. 2014;61(4):809–15. https://doi.org/10.1016/j.jhep.2014.05.003.CrossRefPubMed

23.

Ju W, Chen M, Guo Z, Wang D, Zhu X, Huang J, et al. Allografts positive for hepatitis B surface antigen in liver transplant for disease related to hepatitis B virus. Exp Clin Transplant. 2013;11(3):245–9. https://doi.org/10.6002/ect.2012.0095.CrossRefPubMed

24.

Choi Y, Choi JY, Yi NJ, Lee K, Mori S, Hong G, et al. Liver transplantation for HBsAg-positive recipients using grafts from HBsAg-positive deceased donors. Transpl Int. 2013;26(12):1173–83. https://doi.org/10.1111/tri.12177.CrossRefPubMed

25.

Loggi E, Micco L, Ercolani G, Cucchetti A, Bihl FK, Grazi GL, et al. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol. 2012;56(3):579–85. https://doi.org/10.1016/j.jhep.2011.09.016.CrossRefPubMed

26.

Jiao Z, Zhang Y, Han L, Zeng Y, Yan L. Four-year follow-up of two chronic hepatitis B recipients of hepatitis B surface antigen-positive cadaveric liver grafts from asymptomatic carriers. Hepatol Res. 2011;41(9):846–52. https://doi.org/10.1111/j.1872-034X.2011.00840.x.CrossRefPubMed

27.

Bahde R, Holzen JP, Wolters HH, Schmidt HH, Bock CT, Lugering A, et al. Course of a HBsAg positive liver transplantation in a hepatitis B and D virus coinfected recipient. Ann Hepatol. 2011;10(3):355–60.CrossRefPubMed

28.

Soejima Y, Shimada M, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, et al. Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor. Liver Int. 2007;27(9):1282–6. https://doi.org/10.1111/j.1478-3231.2007.01528.x.CrossRefPubMed

29.

Hwang S, Lee SG, Park KM, Kim KH, Ahn CS, Oh HB, et al. Five-year follow-up of a hepatitis B virus-positive recipient of hepatitis B surface antigen-positive living donor liver graft. Liver Transpl. 2006;12(6):993–7. https://doi.org/10.1002/lt.20799.CrossRefPubMed

30.

Ho JK, Harrigan PR, Sherlock CH, Steinbrecher UP, Erb SR, Mo T, et al. Utilization of a liver allograft from a hepatitis B surface antigen positive donor. Transplantation. 2006;81(1):129–31. https://doi.org/10.1097/01.tp.0000191946.49884.40.CrossRefPubMed

31.

Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl. 2005;11(8):922–8. https://doi.org/10.1002/lt.20471.CrossRefPubMed

32.

Gonzalez-Peralta RP, Andres JM, Tung FY, Fang JW, Brunson ME, Davis GL, et al. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient. Transplantation. 1994;58(1):114–6.CrossRefPubMed

33.

• Chen Z, Ma Y, Dong Y, Chen C, Wang H, Wang T, et al. Utilization of hepatitis B surface antigen-positive donors in liver transplantation for recipients with hepatocellular carcinoma: a retrospective and propensity score matching analysis. PeerJ. 2023;11:e15620. https://doi.org/10.7717/peerj.15620. (Among recipients with HCC, those who received HBsAg-positive allografts (n = 44) had a higher tumor recurrence rate (40.9%) than matched recipients who received HBsAg-negative allografts (n = 44, 27.3%), although the difference did not reach statistical significance. In this study, receipt of HBsAg-positive liver was an independent risk factor for post-OLT mortality (adjusted HR 2.31, 95% CI 1.28–4.16)).CrossRefPubMedPubMedCentral

34.

Lee WC, Chou HS, Lee CS, Wu TH, Wang YC, Cheng CH, et al. Viral activity and outcome of hepatitis B surface antigen-positive grafts in deceased liver transplantation. J Viral Hepat. 2018;25(7):874–7. https://doi.org/10.1111/jvh.12880.CrossRefPubMed

35.

Li Z, Hu Z, Xiang J, Zhou J, Yan S, Wu J, et al. Use of hepatitis B surface antigen-positive grafts in liver transplantation: a matched analysis of the US National database. Liver Transpl. 2014;20(1):35–45. https://doi.org/10.1002/lt.23774.CrossRefPubMed

36.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99. https://doi.org/10.1002/hep.29800.CrossRefPubMed

37.

Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11(4):797–816. https://doi.org/10.1016/j.cld.2007.08.005. (viii).CrossRefPubMed

38.

Bahirwani R, Reddy KR. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl. 2009;15(Suppl 2):S70–4. https://doi.org/10.1002/lt.21900.CrossRefPubMed

39.

Liu JK, Vutien P, Huang DQ, Ishigami M, Landis CS, Nguyen MH, et al. Renal outcomes with tenofovir alafenamide in liver transplant recipients. Clin Gastroenterol Hepatol. 2023;21(2):538-40 e4. https://doi.org/10.1016/j.cgh.2022.01.035.CrossRefPubMed

40.

Scott LJ, Chan HLY. Tenofovir alafenamide: a review in chronic hepatitis B. Drugs. 2017;77(9):1017–28. https://doi.org/10.1007/s40265-017-0754-9.CrossRefPubMed

41.

Cheng CH, Hung HC, Lee JC, Wang YC, Wu TH, Lee CF, et al. Converting from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with hepatitis B following liver transplantation. Ann Transplant. 2023;28:e938731. https://doi.org/10.12659/AOT.938731.CrossRefPubMedPubMedCentral

42.

Wang P, Tam N, Wang H, Zheng H, Chen P, Wu L, et al. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS ONE. 2014;9(8):e104480. https://doi.org/10.1371/journal.pone.0104480.CrossRefPubMedPubMedCentral

43.

Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl. 2013;19(3):268–74. https://doi.org/10.1002/lt.23600.CrossRefPubMed

44.

Pan JJ, Thosani N, Machicao VI, Fallon MB. Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. Hepatol Int. 2011;5(2):635–43. https://doi.org/10.1007/s12072-010-9250-y.CrossRefPubMedPubMedCentral

45.

Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 2006;12(2):253–8. https://doi.org/10.1002/lt.20701.CrossRefPubMed

46.

Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001;34(6):903–10. https://doi.org/10.1016/s0168-8278(01)00080-0.CrossRefPubMed

47.

Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000;6(6):741–8. https://doi.org/10.1053/jlts.2000.18702.CrossRefPubMed

48.

Nourse JP, Jones K, Gandhi MK. Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant. 2011;11(5):888–95. https://doi.org/10.1111/j.1600-6143.2011.03499.x.CrossRefPubMed

49.

Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. 2002;2(10):993–8. https://doi.org/10.1034/j.1600-6143.2002.21019.x.CrossRefPubMed

50.

Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48(6):772–86. https://doi.org/10.1086/597089.CrossRefPubMed

51.

Llado L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl. 2008;14(12):1752–60. https://doi.org/10.1002/lt.21629.CrossRefPubMed

52.

Lamba S, Nagurka R, Desai KK, Chun SJ, Holland B, Koneru B. Self-reported non-adherence to immune-suppressant therapy in liver transplant recipients: demographic, interpersonal, and intrapersonal factors. Clin Transplant. 2012;26(2):328–35. https://doi.org/10.1111/j.1399-0012.2011.01489.x.CrossRefPubMed

53.

Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–9. https://doi.org/10.1053/j.gastro.2014.10.039.CrossRefPubMed

54.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis (Hoboken). 2018;12(1):33–4. https://doi.org/10.1002/cld.728.CrossRefPubMed

55.

Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503–14. https://doi.org/10.1002/hep.22841.CrossRefPubMed

56.

Vutien P, Trinh HN, Garcia RT, Nguyen HA, Levitt BS, Nguyen K, et al. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014;12(8):1363–70. https://doi.org/10.1016/j.cgh.2013.11.036.CrossRefPubMed

57.

Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33(2). https://doi.org/10.1128/CMR.00046-19.

58.

El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-73 e1. https://doi.org/10.1053/j.gastro.2011.12.061.CrossRefPubMed

59.

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. https://doi.org/10.1038/s41572-020-00240-3.CrossRefPubMed

60.

Jiang Y, Han Q, Zhao H, Zhang J. The mechanisms of HBV-induced hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:435–50. https://doi.org/10.2147/JHC.S307962.CrossRefPubMedPubMedCentral

61.

Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol. 2015;62(2):363–70. https://doi.org/10.1016/j.jhep.2014.08.045.CrossRefPubMed

62.

Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53(2):348–56. https://doi.org/10.1016/j.jhep.2010.02.035.CrossRefPubMed

63.

Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, et al. Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir-a propensity score-matched study. J Infect Dis. 2019;219(1):10–8. https://doi.org/10.1093/infdis/jiy391.CrossRefPubMed

64.

Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 2014;147(1):152–61. https://doi.org/10.1053/j.gastro.2014.02.033.CrossRefPubMed

65.

Wang JP, Kao FY, Wu CY, Hung YP, Chao Y, Chou YJ, et al. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study. Cancer. 2015;121(9):1446–55. https://doi.org/10.1002/cncr.29159.CrossRefPubMed

66.

Muhammad H, Tehreem A, Hammami MB, Ting PS, Idilman R, Gurakar A. Hepatitis D virus and liver transplantation: indications and outcomes. World J Hepatol. 2021;13(3):291–9. https://doi.org/10.4254/wjh.v13.i3.291.CrossRefPubMedPubMedCentral

67.

Kamal H, Westman G, Falconer K, Duberg AS, Weiland O, Haverinen S, et al. Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes. Hepatology. 2020;72(4):1177–90. https://doi.org/10.1002/hep.31214.CrossRefPubMed

68.

Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523–32. https://doi.org/10.1016/j.jhep.2020.04.008.CrossRefPubMedPubMedCentral

69.

Buti M, Homs M, Rodriguez-Frias F, Funalleras G, Jardi R, Sauleda S, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18(6):434–42. https://doi.org/10.1111/j.1365-2893.2010.01324.x.CrossRefPubMed

70.

Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS ONE. 2014;9(3):e92062. https://doi.org/10.1371/journal.pone.0092062.CrossRefPubMedPubMedCentral

71.

Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019;19(3):275–86. https://doi.org/10.1016/S1473-3099(18)30663-7.CrossRefPubMed

72.

Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322–31. https://doi.org/10.1056/NEJMoa0912696.CrossRefPubMed

73.

Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389(1):22–32. https://doi.org/10.1056/NEJMoa2213429.CrossRefPubMed

74.

Kang C, Syed YY. Bulevirtide: first approval. Drugs. 2020;80(15):1601–5. https://doi.org/10.1007/s40265-020-01400-1.CrossRefPubMed

75.

• Lee TC, Eckman MH, Shah SA. Cost-effectiveness of utilization of hepatitis B virus-positive liver donors for HBV-negative transplant recipients. J Gastrointest Surg. 2021;25(7):1760–9. https://doi.org/10.1007/s11605-020-04759-4. (The use of HBsAg-positive allografts in HBsAg-negative recipients may be cost-effective at higher MELD scores above 30.)CrossRefPubMed

76.

Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–7. https://doi.org/10.1056/NEJMp1405158.CrossRefPubMed

77.

Smith-Palmer J, Cerri K, Sbarigia U, Chan EKH, Pollock RF, Valentine WJ, et al. Impact of stigma on people living with chronic hepatitis B. Patient Relat Outcome Meas. 2020;11:95–107. https://doi.org/10.2147/PROM.S226936.CrossRefPubMedPubMedCentral

78.

Jin D, Brener L, Treloar C. Hepatitis B-related stigma among Chinese immigrants living with hepatitis B virus in Australia: a qualitative study. Health Soc Care Community. 2022;30(6):e5602–11. https://doi.org/10.1111/hsc.13986.CrossRefPubMedPubMedCentral

Title: Expanding the Donor Pool for Liver Transplantation: Assessing the Potential Use of HBV-Positive Allografts
Authors: Philip Vutien
Mindie H. Nguyen
Publication date: 06-02-2024
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 2/2024
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-024-00653-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2024

A Review of Hepatitis B Reactivation Risk on Immunosuppressants with a Focus on Newer Immunomodulators

Management of Hepatitis B in Pregnancy

Hepatitis B Virus Elimination Strategies

Acute Kidney Injury in Acute on Chronic Liver Failure Versus Decompensated Cirrhosis—What Is the Difference?

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

When to Stop Antiviral Therapy in HBeAg-Negative Patients with Chronic Hepatitis B?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials